Moore Assesses Potential Impact of Antibody-Drug Conjugates in Ovarian Cancer Treatment

Published: Thursday, Apr 18, 2019
Kathleen N.
Moore, MD

Kathleen N. Moore, MD
A potential regulatory approval for mirvetuximab soravtansine could herald increased excitement for antibody-drug conjugates overall in the ovarian cancer paradigm, according to Kathleen N. Moore, MD.

Some of the key takeaways about mirvetuximab soravtansine specifically, she added, is that it is a well-tolerated agent by patients. Physicians, however, need to ensure proper assessment for ocular toxicities, which are inclusive with the therapy.

In an interview with OncLive, Moore, the Jim and Christy Everest Endowed Chair and associate director of clinical research, associate professor, Section of Gynecologic Oncology Director, Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, The University of Oklahoma, discussed the significant unmet needs in the field of ovarian cancer and the recent findings with mirvetuximab soravtansine.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication